IMNM Latest Headlines

Analysts Are Bullish on Top Healthcare Stocks: MetaVia (MTVA), Immunome (IMNM)

at www.tipranks.com (Fri, 6-Mar 8:10 AM)

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Immunome (IMNM)

at www.tipranks.com (Fri, 6-Mar 8:00 AM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunome (IMNM), Hinge Health, Inc. Class A (HNGE) and Stryker (SYK)

at www.tipranks.com (Thu, 5-Mar 8:30 AM)

Evercore ISI Sticks to Their Buy Rating for Immunome (IMNM)

at www.tipranks.com (Wed, 4-Mar 9:56 AM)

Craig-Hallum Sticks to Their Buy Rating for Immunome (IMNM)

at www.tipranks.com (Wed, 4-Mar 9:56 AM)

Piper Sandler Sticks to Its Buy Rating for Immunome (IMNM)

at www.tipranks.com (Wed, 4-Mar 7:56 AM)

Analysts Offer Insights on Healthcare Companies: Staar Surgical (STAA), CVS Health (CVS) and Immunome (IMNM)

at www.tipranks.com (Wed, 4-Mar 7:40 AM)

Immunome: Buy Rating on Best-in-Class Varegacestat Opportunity and Differentiated Next-Generation ADC Oncology Platform

at www.tipranks.com (Wed, 4-Mar 6:25 AM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunome (IMNM) and Sionna Therapeutics, Inc. (SION)

at www.tipranks.com (Tue, 3-Mar 9:00 PM)

Immunome GAAP EPS of -$2.43 misses by $0.16, revenue of $6.9M misses by $0.8M

at seekingalpha.com (Tue, 3-Mar 4:38 PM)

Immunome's $400 Million Public Offering Draws Focus to Cancer Therapy Pipeline and Investor Demand

Market Chameleon (Wed, 17-Dec 7:55 AM)

Immunome to Reveal Pivotal Phase 3 Results for Varegacestat in Desmoid Tumors—What’s at Stake?

Market Chameleon (Mon, 15-Dec 10:28 AM)

Immunome’s Varegacestat Delivers Landmark Efficacy in Phase 3 RINGSIDE Trial for Desmoid Tumors

Market Chameleon (Mon, 15-Dec 7:30 AM)